{"id":"lipid-based-artificial-tear","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Mild ocular discomfort"}]},"_chembl":{"chemblId":"CHEMBL3354642","moleculeType":"Small molecule","molecularWeight":"1826.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This artificial tear product uses lipid components to replicate the lipid layer of the natural tear film, which reduces evaporation and provides sustained lubrication to the eye. By restoring the tear film composition, it alleviates symptoms of dry eye disease and protects the corneal and conjunctival epithelium from damage.","oneSentence":"A lipid-based formulation that mimics the natural tear film to provide lubrication and protect the ocular surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:23.308Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease / Keratoconjunctivitis sicca"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT01760655","phase":"PHASE2","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-12-24","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM","enrollment":62},{"nctId":"NCT03712878","phase":"PHASE2","title":"2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-09-19","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":10},{"nctId":"NCT06913387","phase":"NA","title":"Comparative Efficacy of Lipid Based Artificial Tears vs Aqueous Based Artificial Tears in Managing EDE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2025-03-20","conditions":"Evaporative Dry Eye","enrollment":60},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT05705518","phase":"PHASE4","title":"Artificial Tears, Tear Lipids and Tear Film Dynamics","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2023-01-30","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT06784661","phase":"PHASE4","title":"Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations","status":"NOT_YET_RECRUITING","sponsor":"University of Seville","startDate":"2025-02-01","conditions":"Aberration, Corneal Wavefront","enrollment":40},{"nctId":"NCT06131476","phase":"PHASE1","title":"Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop","status":"COMPLETED","sponsor":"Johnson & Johnson Vision Care, Inc.","startDate":"2020-09-16","conditions":"Visual Acuity","enrollment":32},{"nctId":"NCT03380624","phase":"PHASE4","title":"Tear Lipid Layer Thickness With Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-03-01","conditions":"Dry Eye Syndromes","enrollment":21},{"nctId":"NCT03492541","phase":"NA","title":"Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2018-07-18","conditions":"Dry Eye Disease","enrollment":134},{"nctId":"NCT03706443","phase":"NA","title":"Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-12-05","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases","enrollment":24},{"nctId":"NCT02956083","phase":"NA","title":"The Effect of Tear Supplements on Contact Lens Comfort","status":"COMPLETED","sponsor":"University of the Incarnate Word","startDate":"2014-07","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":30},{"nctId":"NCT00534391","phase":"PHASE3","title":"Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2007-09","conditions":"Hordeolum","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lipid-Based Artificial Tear","genericName":"Lipid-Based Artificial Tear","companyName":"University of Seville","companyId":"university-of-seville","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lipid-Based Artificial Tear is a small molecule intervention used to treat various eye conditions, including Dry Eye Syndromes, Keratoconjunctivitis Sicca, and Lacrimal Apparatus Diseases. It is studied in clinical trials for its effects on conditions such as Aberration, Corneal Wavefront, Evaporative Dry Eye, and Keratoconjunctivitis Sicca.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}